AR016001A1 - Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente - Google Patents

Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente

Info

Publication number
AR016001A1
AR016001A1 ARP980105513A ARP980105513A AR016001A1 AR 016001 A1 AR016001 A1 AR 016001A1 AR P980105513 A ARP980105513 A AR P980105513A AR P980105513 A ARP980105513 A AR P980105513A AR 016001 A1 AR016001 A1 AR 016001A1
Authority
AR
Argentina
Prior art keywords
patient
integer
manufacture
amine polymers
alifatic
Prior art date
Application number
ARP980105513A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR016001A1 publication Critical patent/AR016001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
    • C12Y102/03004—Oxalate oxidase (1.2.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01002—Oxalate decarboxylase (4.1.1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de polímeros de amina alifática para la fabricacion de un medicamento para reduccion de los niveles de oxalato en un paciente que lo necesiteconsistente en administrar a dicho paciente una cantidad terapéuticamente efectiva de uno o más polímerosde amina alifática. En una realizacion elpolímero posee una unidad repetitiva que tiene la formula seleccionada de: formulas (I) y sus sales y copolímeros, donde n es un numero enteropositivo y x es cero o un numero entero entre 1 y 4, y y z son numeros enteros de uno o más y R, R1, R2 y R3, independientemente, son H o un grupo alquilo,alquilamino o arilo substituido o no substituido. Más en particular el polímero es un polímero entrecruzado que tiene una unidad repetitiva de formula(II) y sussales, donde n es un numero entero positivo y x es cero o un numero entero entre 1 y 4. Los polímeros son particularmente utiles en el tratamientode cálculos urinarios.
ARP980105513A 1997-11-05 1998-11-03 Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente AR016001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/964,956 US5985938A (en) 1997-11-05 1997-11-05 Method for reducing oxalate

Publications (1)

Publication Number Publication Date
AR016001A1 true AR016001A1 (es) 2001-05-30

Family

ID=25509224

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105513A AR016001A1 (es) 1997-11-05 1998-11-03 Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente

Country Status (10)

Country Link
US (3) US5985938A (es)
EP (2) EP1645278A3 (es)
JP (1) JP4452402B2 (es)
AR (1) AR016001A1 (es)
AU (1) AU1364799A (es)
CA (1) CA2349620C (es)
DE (1) DE69833134T2 (es)
TW (1) TW585772B (es)
WO (1) WO1999022744A1 (es)
ZA (1) ZA989671B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US8486389B2 (en) 1997-05-23 2013-07-16 Oxthera, Inc. Compositions and methods for treating or preventing oxalate-related disease
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
GB9927088D0 (en) * 1999-11-17 2000-01-12 Secr Defence Use of poly(diallylamine) polymers
DE10028167B4 (de) * 2000-06-09 2004-02-19 Storch, Rüdiger, Dr. Verwendung von Calciumsalzen zur Entgegenwirkung der Bildung von Oxalatharnsteinen
EP1923064B1 (en) 2001-04-18 2017-06-28 Genzyme Corporation Use of amine polymer for lowering serum glucose
WO2002085379A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for improving vascular access in patients with vascular shunts
AU2002257145B2 (en) * 2001-04-18 2005-06-02 Genzyme Corporation Method for lowering serum glucose
JP2004528332A (ja) * 2001-04-18 2004-09-16 ジェンザイム コーポレーション 痛風を治療する方法および尿酸を結合する方法
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
KR20040018357A (ko) * 2001-04-18 2004-03-03 젠자임 코포레이션 저염 형태의 폴리알릴아민
BR0209124A (pt) 2001-04-18 2005-02-09 Genzyme Corp Método para tratar uma sìndrome x ou inibir o inìcio dos sintomas da sìndrome x e uso de uma quantidade terapeuticamente efetiva de um sal de pelo menos um polìmero de amina alifática
ATE499943T1 (de) * 2001-04-23 2011-03-15 Shire Int Licensing Bv Verwendung von lanthankarbonat zur prävention von nierensteinleiden
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
WO2003042380A2 (en) * 2001-10-05 2003-05-22 Ixion Biotechnology, Inc. Materials and methods for reducing oxalate concentrations in fluids
US6600011B2 (en) * 2001-10-09 2003-07-29 Genzyme Corporation Process for purification and drying of polymer hydrogels
WO2003031501A1 (en) * 2001-10-09 2003-04-17 Genzyme Corporation Process for purification and drying of polymer hydrogels
AU2003282867A1 (en) * 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
GB2456253B (en) 2004-03-30 2009-08-26 Relypsa Inc Ion binding polymers and uses thereof
EP1755655A4 (en) * 2004-05-07 2011-03-30 Oxthera Inc METHOD AND COMPOSITIONS FOR REDUCING OXALATE CONCENTRATIONS
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
EP1830832A1 (en) * 2004-12-30 2007-09-12 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
JP2009507019A (ja) 2005-09-02 2009-02-19 ジェンザイム・コーポレーション リン酸塩を除去する方法およびそれに使用される重合体
KR101574072B1 (ko) 2005-09-15 2015-12-04 젠자임 코포레이션 아민 중합체에 대한 샤셋 제형
CA2626734A1 (en) * 2005-11-08 2007-05-18 Genzyme Corporation Magnesium-containing polymers for the treatment of hyperphosphatemia
PL1962873T3 (pl) * 2005-12-14 2014-03-31 Oxthera Intellectual Property Ab Kompozycje farmaceutyczne zawierające bakterie zmniejszające ilość szczawianu
ATE499111T1 (de) * 2005-12-16 2011-03-15 Oxthera Inc Zusammensetzungen und verfahren zur oxalatreduktion
JP2009536246A (ja) * 2006-05-05 2009-10-08 ゲンズイメ コーポレーション ホスフェート捕捉剤としてのアミン縮合重合体
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
AU2007272494B2 (en) 2006-07-14 2011-07-28 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
CA2658338A1 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
JP2009545622A (ja) 2006-08-02 2009-12-24 アルタス ファーマシューティカルズ インコーポレイテッド 結晶性シュウ酸デカルボキシラーゼおよび使用方法
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
ES2573636T3 (es) * 2006-10-25 2016-06-09 Wisconsin Alumni Research Foundation Métodos para reducir la absorción de fosfato empleando un anticuerpo anti-Npt2B
US20100143385A1 (en) * 2006-10-26 2010-06-10 Mark Cook Methods for reducing phosphate absorption
WO2008076242A1 (en) 2006-12-14 2008-06-26 Genzyme Corporation Amido-amine polymer compositions
US20100129309A1 (en) * 2007-02-23 2010-05-27 Dhal Pradeep K Amine polymer compositions
US20100196305A1 (en) * 2007-03-08 2010-08-05 Dhal Pradeep K Sulfone polymer compositions
EP2139461A2 (en) * 2007-03-20 2010-01-06 Recepticon Aps Amino derivatives to prevent nephrotoxicity and cancer
WO2008133954A1 (en) * 2007-04-27 2008-11-06 Genzyme Corporation Amido-amine dendrimer compositions
WO2009078958A1 (en) * 2007-12-14 2009-06-25 Genzyme Corporation Coated pharmaceutical compositions
FR2928373B1 (fr) 2008-03-05 2010-12-31 Centre Nat Rech Scient Polymere derive de la polyethylenimine lineaire pour le transfert de gene.
WO2009154747A1 (en) * 2008-06-20 2009-12-23 Genzyme Corporation Pharmaceutical compositions
JPWO2010123039A1 (ja) * 2009-04-21 2012-10-25 株式会社医学生物学研究所 生物学的材料の不動化を行うための組成物
US9714456B2 (en) 2013-01-18 2017-07-25 Allena Pharmaceuticals, Inc. Crystallized oxalate decarboxylase and methods of use
US20160024233A1 (en) * 2013-03-15 2016-01-28 Genzyme Corporation Sequestrants of advanced glycation end product (age) precursors
US11077238B2 (en) 2013-06-07 2021-08-03 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
US10435528B2 (en) 2013-09-17 2019-10-08 Aquanano Llc High-capacity anion exchange materials
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
KR20180044225A (ko) 2015-04-02 2018-05-02 캡토자임, 엘엘씨 불용성 및 가용성의 옥살레이트의 분해를 위한 고효율의 옥살레이트 분해 효소
GB201718803D0 (en) * 2017-11-14 2017-12-27 Phoenix Molecular Pte Ltd Method for isolation of nucleic acids
US11993670B2 (en) 2018-06-06 2024-05-28 The Board Of Trustees Of The University Of Illinois Zwitterionic biocompatible polymers, methods, and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198396A (en) * 1974-07-03 1980-04-15 Warren-Teed Laboratories, Inc. Dissolution of gallstones
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
JPS60202869A (ja) * 1984-03-26 1985-10-14 Ajinomoto Co Inc 大環状ポリアミン誘導体及びその用途
DE3727082A1 (de) * 1987-08-14 1989-02-23 Goedecke Ag Pharmazeutische zubereitungen zur behandlung der urolithiasis
US5244913A (en) * 1991-11-19 1993-09-14 Baxter International Inc. Compositions and methods for dissolving body calculi
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5703188A (en) * 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
EP0934352B1 (en) * 1996-10-23 2007-05-02 Dow Global Technologies Inc. Water-soluble polymers for the reduction of dietary phosphate or oxalate absorption
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate

Also Published As

Publication number Publication date
WO1999022744A1 (en) 1999-05-14
US6177478B1 (en) 2001-01-23
AU1364799A (en) 1999-05-24
JP2001521902A (ja) 2001-11-13
TW585772B (en) 2004-05-01
CA2349620A1 (en) 1999-05-14
JP4452402B2 (ja) 2010-04-21
US6281252B1 (en) 2001-08-28
EP1645278A3 (en) 2007-11-14
DE69833134D1 (de) 2006-03-30
EP1645278A2 (en) 2006-04-12
ZA989671B (en) 1999-04-28
US5985938A (en) 1999-11-16
EP1044008A1 (en) 2000-10-18
DE69833134T2 (de) 2006-08-10
EP1044008B1 (en) 2006-01-04
CA2349620C (en) 2008-04-08

Similar Documents

Publication Publication Date Title
AR016001A1 (es) Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente
DK1169298T3 (da) Farmaceutiske forbindelser
FI875229A (fi) Menetelmä uusien farmakologisesti aktiivisten katekolijohdoksien valmistamiseksi
GT199900150A (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas.
TR199800019T1 (xx) Trombosit topaklanmas�n� �nleyici yeni maddeler.
ES2033774T5 (es) Derivados antiviricos fosfonometoxialquilenicos de purina y pirimidina.
PA8432901A1 (es) Compuestos de piridilpirrol
AR005229A1 (es) Un derivado de 2,3-dioxo-1,2,3,4-tetrahidro-quinoxaliil y una composicion farmaceutica que lo comprende.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ATE88468T1 (de) Arylalkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
ES2058596T3 (es) Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso.
DE69615555T2 (de) 6-carboxamido-dihydropyran-derivate
AR012723A1 (es) Derivados triptolidos utiles en el tratamiento de enfermedades autoinmunes y usos en la fabricacion de medicamentos
CO5070654A1 (es) Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden
DK0553016T3 (da) Hidtil ukendte naphtalenamider og -sulfonamider, fremgangsmåder til deres fremstilling samt farmaceutiske midler indeholdende dem
ES2127762T3 (es) Quinoleinas 2-sustituidas para el tratamiento de las leismaniosis.
KR880011112A (ko) 벤즈아제핀 설폰아미드 화합물
DE69426908D1 (de) Derivate der Phosphonsäure, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
DK624989D0 (da) Hidtil ukendte forbindelser
AR014539A1 (es) Derivados de 5'-desoxicitidina, una composicion farmaceutica y kit que los comprende, el uso de los mismos para la fabricacion de un medicamento
CO4650030A1 (es) Derivados de n-(benzotiazol-2-il) piperidina-1-etanamina, proceso para su preparacion y producto farmaceutico que los contiene
SE9603285D0 (sv) New compounds
JPS6470412A (en) Medicinal composition
ES2146722T3 (es) Nuevos analogos de la acronicina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DK0466586T3 (da) Disubstituerede polymethyleniminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem

Legal Events

Date Code Title Description
FB Suspension of granting procedure